Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Spironolactone commonly causes menstrual changes in females, including irregular cycles, spotting, or missed periods, because it blocks androgen and affects hormone signaling. It can also raise potassium levels (hyperkalemia), which may show up as muscle weakness, fatigue, tingling, or an irregular heartbeat and sometimes requires blood monitoring, especially with kidney issues, ACE inhibitors, or potassium supplements. Breast tenderness, swelling, and enlargement are also frequently reported, and any new lump, one-sided change, or nipple discharge deserves prompt evaluation. Dose, duration, age, and other medications all influence which effects appear and how serious they are, so there are several important factors to consider, described in more detail below.
Because these symptoms can range from harmless and temporary to signs of a potassium imbalance that needs urgent attention, it helps to sort out what you are experiencing before your next appointment; a free, instant, online symptom check can help you organize your symptoms, understand possible causes, and decide whether to wait, call your prescriber, or seek care now.
Last reviewed for medical accuracy: 09/28/2026
Spironolactone is often prescribed for acne, hirsutism and fluid retention. As a potassium-sparing diuretic with antiandrogen properties, it can help balance hormones and clear skin. However, like all medications, it carries potential side effects—especially in females. Understanding these risks and how to manage them can help you make informed decisions about your health.
Spironolactone blocks aldosterone receptors in your kidneys, preventing sodium reabsorption and promoting water loss. It also inhibits androgen receptors and reduces testosterone production. This dual action can:
But because it alters hormone levels and electrolyte balance, you may notice changes in your periods, potassium levels, and breast tissue.
Hormonal shifts caused by spironolactone can affect menstrual cycles. Common changes include:
Why it happens:
Tips to manage:
Spironolactone can raise blood potassium because it reduces potassium excretion. High potassium (hyperkalemia) can be serious.
Often mild or no symptoms at first. Watch for:
While gynecomastia (breast enlargement) is more common in men, women taking spironolactone may notice:
These changes stem from hormone shifts—particularly increased estrogen-to-androgen ratio.
Besides periods, potassium and breasts, you may experience:
These effects tend to be temporary. If they persist beyond 2–3 months or interfere with daily life, speak with your healthcare provider.
While uncommon, watch for warning signs that require immediate medical attention:
If you experience any of these, call emergency services or go to the hospital right away.
Not sure if your symptoms are related to spironolactone? Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide if you need medical attention or a change in therapy.
Discuss any side effects that:
Always tell your healthcare provider about all medications, supplements and herbal products you use.
Spironolactone can be a very effective treatment for acne, hirsutism and fluid retention in females. By staying informed about spironolactone side effects in females—especially changes in periods, potassium levels and breast tissue—you can work with your doctor to maximize benefits and minimize risks.
If you notice anything serious or life-threatening, speak to a doctor right away. Regular monitoring, honest communication and healthy lifestyle habits will help you get the most out of your treatment while keeping you safe.
(References)
* Gianetto-Berruti A, Feyles V. Premenstrual syndrome. Minerva Ginecol. 2002 Apr;54(2):85-95. PMID: 12032448.
* Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med. 2004 Dec 2;351(23):2448-50; author reply 2448-50. PMID: 15580679.
* Ueno H, Yoshimura M, Nakayama M, Yamamuro M, Nishijima T, Kusuhara K, Nagayoshi Y, Kojima S, Kaikita K, Sumida H, Sugiyama S, Ogawa H. Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome. Int J Cardiol. 2010 Jan 21;138(2):174-81. doi: 10.1016/j.ijcard.2008.08.011. Epub 2008 Sep 19. PMID: 18804879.
* Erden I, Yalcin S, Ozhan H. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone. Kardiol Pol. 2010 Sep;68(9):1043-5; discussion 1046. PMID: 20859899.
* Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016 Sep;4(9):726-35. doi: 10.1016/j.jchf.2016.06.003. Epub 2016 Aug 10. PMID: 27522631; PMCID: PMC5010507.
* Bristow MR, Sharma K, Assmann SF, Linas S, Gersh BJ, Grady C, Rice MM, Singh S, Boineau R, McKinlay SM, Greenberg BH. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. Eur J Heart Fail. 2017 Apr;19(4):457-465. doi: 10.1002/ejhf.686. Epub 2016 Nov 21. PMID: 27873428.
* Sconfienza E, Riancho J, Gebara N, Ferrão D, Burrello J, de Freminville JB, Deflorenne E, Lorthioir A, Azizi M, Amar L. Efficacy and Safety of Treatment With Low Doses of Spironolactone in Patients With Primary Aldosteronism: A Retrospective Observational Study in a Tertiary Center. Hypertension. 2026 May;83(5):e24881. doi: 10.1161/HYPERTENSIONAHA.125.24881. Epub 2026 Jan 12. PMID: 41521906.
* Bagattoli V, Dos Santos HS, Giorgi J, Batista PG, Lopes SC, Gambetta MV, de Oliveira Fischer Bacca C. Finerenone, eplerenone, and spironolactone in heart failure with preserved ejection fraction: a Bayesian network meta-analysis of efficacy and safety. Eur J Heart Fail. 2026 Sep 15;28(3):473-483. doi: 10.1093/ejhf/xuag083. PMID: 41831311.
* Böhm M, Abdullakutty J, Bauersachs J, Bavendiek U, Bayes-Genis A, Bhattacharyya K, Biegus J, Bozkurt B, Butler J, Ezhilan J, Ferreira JP, Girerd N, Gupta R, Hiremath J, Jhund P, Kessler T, Kumar D, Markwirth P, Marx N, McDonagh T, Navasundi G, Pande A, Petrie M, Ponikowski P, Rakisheva A, Rosano G, Sato N, Savarese G, Sharma K, Sliwa K, Somaraju B, Sossalla S, Störk S, Tokcan M, Tsioufis K, Zhang Y, Zhang J, Zieroth S, Zannad F. European Journal of Heart Failure International Expert Position Paper-Utilization, optimization, and clinical benefits of steroidal mineralocorticoid receptor antagonists in heart failure with a reduced ejection fraction. Eur J Heart Fail. 2026 Sep 15;28(3):513-534. doi: 10.1093/ejhf/xuag106. PMID: 41955577.
* Kendrick JB, Dixon AM. Review of Hyperkalemia Profile for Mineralocorticoid Receptor Antagonist in Patients with Chronic Kidney Disease and Type 2 Diabetes. Cardiorenal Med. 2026;16(1):312-320. doi: 10.1159/000552030. Epub 2026 Apr 30. PMID: 42060537; PMCID: PMC13322682.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.